Substance use disorders (SUDs) are associated with progressive decrements to physical and mental health, and frequently lead to death via overdose, suicide, or co-occurring disease (Le Moal & Koob, 2007). The goal of many SUD treatment programs is to promote abstinence from illicit drugs and/or alcohol, however achieving abstinence during a treatment episode is extremely challenging (Peele, 2016). If abstinence is achieved, lapses and relapses to drugs and alcohol are common. As such, clinical trials on medication and behavioral strategies to achieve and maintain abstinence often fail despite robust preclinical findings that suggest those strategies would be efficacious in humans (Jones et al., 2021). Harm reduction outcomes, including a reduction in drug and alcohol use and/or risky behaviors, are more achievable for a number of persons struggling with SUDs. Treatment strategies that promote harm reduction therefore have the potential to reach a broad population of persons with SUDs, and from a public health standpoint, harm reduction can improve health and save lives.In this special issue titled "Utilizing translational approaches to advance harm reduction strategies for substance use disorders," we highlight research that outlines the benefits of harm reduction across drug classes. Through demonstration of broad benefits of harm reduction across different drugs of abuse, we hope to advance the field toward having harm-related outcomes included in both clinical and preclinical research. There are eight articles in this special issue that demonstrate the importance of harm reduction. Dolan et al.This document is copyrighted by the American Psychological Association or one of its allied publishers.